Celon Pharma Says FDA Deems Phase III Study Concept For CPL'36 Treatment Reasonable

Reuters
2026.02.13 16:18
Feb 13 (Reuters) - Celon Pharma SA (CLNP.WA) : * ANNOUNCES COMPLETION OF ANALYSIS OF WRITTEN RESPONSES FROM FDA REGARDING CPL'36 FOR PARKINSON'S DISEASE-INDUCED DYSKINESIA (PD-LID) * FDA DEEMS PROPOSED PHASE III STUDY CONCEPT FOR CPL'36, INCLUDING DESIGN, DURATION, AND PRIMARY ENDPOINT, AS REASONABLE * BELIEVES FDA STANCE SUPPORTS CONTINUING PHASE III PROGRAM AND WILL INCORPORATE RECOMMENDATIONS INTO PROTOCOLS Source text: Further company coverage: (CLNP.WA)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer